3
Registered trials
0
Recruiting
3
Unique sponsors
5
Unique IMPs
3
Commercial trials
Drug classes (ATC)
—
ATC code not specified
2
L
Oncology (ATC L)
1
M
Musculoskeletal (ATC M)
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
2 substances
Proteasome inhibitor
1 substance
Antimetabolite
1 substance
Monoclonal antibody (chimeric)
1 substance
Phase IV:
1
Phase I (Other):
1
Phase I (First in Human):
1
Phase IV
1 trial-
EndedAlexion Pharmaceuticals Inc. CommercialBORTEZOMIB; METHOTREXATE DISODIUM; RITUXIMAB
Phase I (Other)
1 trial-
EndedAM-Pharma B.V. CommercialILOFOTASE ALFA
Phase I (First in Human)
1 trial-
PendingAlesta Therapeutics B.V. CommercialALE1
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| AM-Pharma B.V. | Commercial | 1 | Phase I (Other) | 0 |
| Alexion Pharmaceuticals Inc. | Commercial | 1 | Phase IV | 0 |
| Alesta Therapeutics B.V. | Commercial | 1 | Phase I (First in Human) | 0 |
New trials by year
2023
1